Clearance Summary
RAPIDPOINT 405 NEONATAL BILIRUBIN received FDA 510(k) clearance under submission number K110277, sponsored by Siemens Healthcare Diagnostics. The device was reviewed via the Traditional premarket notification pathway and assigned to the Clinical Chemistry review panel. The statutory decision date of record is 2011-08-15.
- Submission: K110277
- Applicant / Sponsor: Siemens Healthcare Diagnostics
- Clearance pathway: Traditional
- Review panel: Clinical Chemistry
- Device class: Class I
- Regulation citation: 21 CFR 862.1113
- Decision date: 2011-08-15
Classification & Regulation
This clearance is catalogued under FDA product code MQM and 21 CFR 862.1113, within the Clinical Chemistry review panel as a Class I device.